Abstract PD10-03: Subgroup analyses of VERITAC-2: A phase 3 trial of vepdegestrant, a PROTAC estrogen receptor (ER) degrader, versus fulvestrant in ER-positive/ human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (aBC)
Year: 2026
Type: conference-abstract
Source: Clinical Cancer Research
Institutions: Sarah Cannon, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Memorial Sloan Kettering Cancer Center, Fudan University, Fudan University Shanghai Cancer Center, Centre Georges François Leclerc, Institut de Cancérologie de l'Ouest, IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola, First Hospital of Jilin University, Sunnybrook Health Science Centre, University of Toronto, Odette Cancer Centre, The University of Osaka, Hospital General Universitario de Elche, Pfizer (United States), Arvinas (United States)
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7129492091